Patient and caregiver commitment, together with imaging and appropriate clinical assessments, determine developmental success in neurology indications. That’s why Worldwide focuses on study designs that offer less hassle for families, and science that leaves less subjectivity for interpreting efficacy.
When you have a neurology program to develop, you want a service provider that performs above the rest in its ability to deliver a great experience on a reasonable budget. You want data quality and innovative design approaches that deserve your loyalty.
Our neurology team unites thoughtful logistics with a patient-forward strategy that demonstrates their in-depth knowledge of the therapeutic area. Our experts can boost the strength of your program through technology and design approaches right from the start, providing the ideal imaging and outcome measures to drive success for the life of your program.
President of Neuroscience Business Unit
Tamara Ast, PhD, President of the CNS Business Unit at Worldwide Clinical Trials, oversees a team of experienced neuroscience clinical research professionals for neurological, psychiatric, and pain indications. With more than 25 years’ industry experience, she has provided leadership for project management and operations delivery at Worldwide. Her affinity for working in multicultural environments has contributed to her commitment to diversity. She empowers large teams across multiple regions globally to deliver regulatory, scientific, medical, and operational excellence to our customers.
Vice President, Scientific Solutions, Neuroscience
Executive Director, Project Management, Neurology and Rare Diseases
Senior Director, Therapeutic Strategy Lead, Neuroscience
Worldwide began as a neurology-focused CRO, and we pair our long-standing expertise and strong heritage with a flexibility and nimbleness to adapt to your study’s unique needs and to advance neurology research.
Our medical, scientific and operational teams include seasoned neurologists and neuroscientists working closely to drive impeccable operational study execution, for everything from first-in-human to large, global Phase III programs.
From Parkinson’s and multiple sclerosis to epilepsy and amyotrophic lateral sclerosis, Worldwide has done it all. We’ve worked with stimulants, selective inhibitors, reuptake inhibitors, neurotoxin proteins, long-acting injectables, and much more.
Worldwide was founded to help improve research for neurology patients. Decades later, we’ve done it all, working on a dizzying number of compounds and indications in every phase. Now Worldwide is one of the few full-service CROs that provides integrated rater training, scale management, bespoke assessment development, and a broad range of other highly specialized consulting services in addition to our top-notch global network of study execution experts.
Our Cognitive Task Force and scale development work speak volumes about our commitment to Alzheimer’s and dementia research. At Worldwide, we design and execute rigorous, compassionate studies we’d be happy to have our own family and friends take part in, carefully protecting the patient experience and maintaining compelling data integrity to get products to market even in this competitive research space.
Worldwide leads the way in best practice development for pain and addiction research. We have seen it all, which helps us offer the right blend of tried-and-true logistics, creative study designs, and thoughtful outcomes measures to augment objectivity in this otherwise nebulous field of research.
Rare neurological diseases each have unique hurdles for developing compelling outcomes assessments that can demonstrate efficacy with small patient populations. Worldwide is a leader in rare disease recruitment, novel endpoint development, and innovative study designs. We deliver specialty studies that apply our overarching knowledge in neurological conditions and rare diseases to thoughtful study designs, respecting patient communities and generating the data sponsors need to advance their compound to market.
A crowded research space makes it difficult to weed the subjectivity out of the science—which demands a CRO with psychiatry know-how from the ground up and the top down. Our proven track record for patient recruitment and engaged investigator networks speaks volumes about our expertise in psychiatric trial development and execution.
We’ve been a part of industry-sponsored psychedelic trials since they began. Our Psychedelic Center of Excellence has a comprehensive approach to the complex operational delivery of these trials and working with patients and sites for study success.